Search Results
Jan 09, 2026, 16:00 ET Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
TWINPEAK study, which includes greater than 100 patients in the United States2 mg/kg QW spevatamig + GnP showed promising efficacy when compared with published studies of GnP in 1L mPDAC, while data for 3 mg/kg QW spevatamig + GnP is still maturingSpevatamig is a novel immunotherapy which
More news about: Phanes Therapeutics, Inc.
Jan 09, 2026, 12:40 ET M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio
content:https://www.prnewswire.co.uk/news-releases/mg-champions-uk-innovation-in-drug-discovery-by-leading-us50-million-funding-round-for-biotech-company-bitbio-302657492.html
More news about: bit.bio; M&G Investments
Jan 09, 2026, 12:31 ET M&G champions UK innovation in drug discovery by leading US$50 million funding round for biotech company bit.bio
multimedia:https://www.prnewswire.com/news-releases/mg-champions-uk-innovation-in-drug-discovery-by-leading-us50-million-funding-round-for-biotech-company-bitbio-302657488.htmlSOURCE
More news about: bit.bio; M&G Investments
Jan 09, 2026, 07:00 ET Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively. Skin CancersIn ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients. AlopeciaIn
More news about: Insmed Incorporated
Jan 08, 2026, 19:00 ET Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
received three monthly doses of either OLN324 2mg, OLN324 4mg, or faricimab 6mg. Patients were evaluated at Weeks 1, 4, 8, 12, 16, and 20. Primary efficacy outcomes were evaluated at Week 12; results achieved at Week 12 with OLN324 2 mg were similar to 4 mg.A favorable safety profile was observed
More news about: Innovent Biologics
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial. Learn more Zepbound is a prescription medicine. For more
More news about: Eli Lilly and Company
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms." In light of the trial results, Insmed decided to discontinue development of brensocatib. On this news, Insmed's stock price
More news about: Pomerantz LLP
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rezolute, Inc. - RZLT
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
hypoglycemia events by self monitored blood glucose. There was an approximate 45% reduction in hypoglycemia events observed at the top ersodetug dose (10 mg/kg), which was not statistically significant compared to the placebo group, which experienced a 40% improvement. Furthermore, the study did not meet its
More news about: Pomerantz LLP
Jan 08, 2026, 09:00 ET RYZE Launches Nationwide at Target, Marking the Brand's First National Retail Launch
and velvety instant latte made with 1,000 mg SUPER6™ organic mushroom blend per serving, ~50 mg caffeine, 5 sticks per cartonMocha Latte: Rich and decadent instant latte made with 1,000 mg SUPER6™ organic mushroom blend per serving, ~50 mg caffeine, 5 sticks per cartonCaramel
More news about: RYZE Inc
Jan 08, 2026, 09:00 ET Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones
patients were enrolled in the initial cohorts of the Phase 1b trial. Patients were first enrolled in the 80 mg once daily (QD) cohort. Subsequent patients were randomized to either 60 mg QD or 120 mg QD.Patients enrolled were heavily pretreated, consistent with patients from previously reported
More news about: Enliven Therapeutics, Inc.
Jan 08, 2026, 09:00 ET Francelys Infante Launches N2B4B: A Holistic Self-Care Brand Rooted in Resilience and Self-Worth
yourself.Nutrition Fact Panel:Vitamin C (as Sodium Ascorbate) 100 mgBiotin 4500 mcgSodium 20 mgPotassium 9 mgProprietary Blend 550 mg: Antioxidant Blend: Ascorbic Acid, Punica Granatum (Pomegranate) Fruit Extract (and) Decaffeinated
More news about: N2B4B
Jan 08, 2026, 09:00 ET Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients.Fifteen leading university hospitals in Germany are participating
More news about: Acousia Therapeutics GmbH
Jan 08, 2026, 08:00 ET High on Rye: Ivy Hall and Steingold's Deli Debut Chicago's First Cannabis-Infused Mustard for National Pastrami Day
Available on January 14, 2026, the limited edition offering features a 5mg infused mustard dose and will be sold at Ivy Hall Logan Square (3115 W. Armitage Ave., Chicago, IL 60647) for adults 21 and over beginning at 12 p.m.,
More news about: Ivy Hall
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly treatment arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo.About GLP-1 and Dual GLP-1/GIP AgonistsActivation of the glucagon-like peptide
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 06:00 ET Tim Hortons® U.S. kicking off 2026 with value offers, protein beverages, and other new drinks and baked goods!
recommended for children, pregnant or nursing women, and persons sensitive to caffeine. Each 16oz TimsBoost Energy Infusion with Red Bull® contains 80 mg of caffeine.
More news about: Tim Hortons
Jan 08, 2026, 04:01 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
targeting rare and severe disease areas with high unmet needs.Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 08, 2026, 03:42 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
targeting rare and severe disease areas with high unmet needs.Foresee's product portfolio includes late and early-stage programs. CAMCEVI 42 mg, for the treatment of advanced prostate cancer, is now approved in the U.S., Canada, EU, Taiwan, Israel, and the UK and was launched in the U.S. in April
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 07, 2026, 17:31 ET Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight
moderate-to-severe psoriasis, significantly higher proportions of patients treated with TAK-279 achieved PASI 75, PASI 90, and PASI 100 at doses of 5 mg, 15 mg, and 30 mg versus placebo at Week 12. The program has advanced into Phase III development, with a head-to-head trial against deucravacitinib expected to
More news about: DelveInsight Business Research, LLP
Jan 07, 2026, 11:55 ET One Batch of Roasted Potatoes, Three Easy Weeknight Dinners
an excellent source of Vitamin C (27g)Is a good source of potassium (620mg)Give you the energy you need to perform at your best (26g)Has protein (3g), iron (1.1mg), fiber (2g), and Vitamin B6 (0.2mg)"Make-ahead potatoes are a weeknight lifesaver, and reheating them
More news about: Potatoes USA
Jan 07, 2026, 09:32 ET Doctor's Best Celebrates FDA Decision on NMN Supplements, Relaunches Product Line
Coq10 (150 mg), NMN+ (200 mg) and
More news about: Doctor's Best
Jan 07, 2026, 09:05 ET Study showed MiniMed™ 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus
diabetes populations:TIR: 76.3% recommended optimal settings vs. 69.3% for non-recommended optimal usersMean Sensor Glucose: 149 mg/dL vs. 160 mg/dLGlucose Management Indicator: 6.9% vs. 7.1%More than 61% of recommended optimal setting users met all three of the ADA recommended
More news about: Medtronic plc
Jan 07, 2026, 08:47 ET Morphy's High-Powered Dec. 16-18 Firearms & Militaria Auction Tops $7M, With Robust Prices Paid For Fine, Rare Guns With Documented History
original H&K sight adjustment tool. It sold above its high estimate, for $84,000.The second NFA lot of special note was a very early German Model MG42/59 machine gun imported and registered by Cadillac Gage (Warren, Mich.) and used to bore-sight vehicle turrets. It had a scarce configuration with
More news about: Morphy Auctions
Jan 07, 2026, 08:04 ET FDA Approves New 2-Gram Presentation of Fibryga®, Enhancing Convenience and Precision in Treating Acquired Fibrinogen Deficiency
deficiency has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.Fibryga® is made
More news about: Octapharma
Jan 07, 2026, 07:00 ET Ozempic From India Now Available at Prices Below U.S. Retail via SaveRxCanada.to International Pharmacy Services
https://saverxcanada.to/drugs/Ozempic/prefilled%2Bpen/0.25mgOzempic Prefilled Pen 0.5 mg (1.5 mL)
More news about: SaveRxCanada.to